A complete list of the members of the SPCG-5 Study Group is given in the Appendix.
Introduction
Prostate cancer is the most commonly diagnosed male cancer in Scandinavia and most other Western countries, with 10 000 incident cases being diagnosed in Sweden 2016 [1] . The introduction of PSA as a screening tool at the end of the last century has led to a marked shift in stage of the disease at diagnosis, with an increasing proportion of prostate cancer cases being diagnosed at a clinically localised stage. Despite this, advanced and metastatic stages continue to be found at the time of diagnosis.
Currently~12% of men with newly diagnosed prostate cancer have skeletal metastases (The Swedish National Prostate Cancer Register [NPCR] ), and anaemia is present in 21-78% of these [1, 2] . Androgen-deprivation therapy (ADT) has long been the systemic treatment of choice for this condition [3] . A large number of adverse events, including anaemia, have been documented during ADT in metastatic [4] [5] [6] , as well as non-metastatic [7] [8] [9] [10] prostate cancer. Many experimental [11, 12] and clinical [13, 14] studies over several decades have shown that ADT per se is associated with a decrease in Hb concentration. However, it is difficult to explain the complex changes in Hb concentration during ADT for bone-metastatic (Stage M1b) prostate cancer, from the results of these studies [15, 16] . Analyses by the Southwest Oncology Group (SWOG) showed that an increase in Hb concentration after 3 months of ADT was associated with an unexpected reduction in survival [17] , although this could not be confirmed in other studies. Investigations linking Hb concentrations during the first year of ADT for M1b prostate cancer with subsequent survival are still lacking. The long-term association between changes in Hb concentration and survival after ADT remains unknown.
In the present study we used patient data from our large cohort of hormone-na€ ıve patients with M1b prostate cancer to compare changes in Hb concentration during the first 12 months of ADT with relevant clinical covariates and survival over a 10-year period.
Our hypothesis was that the pattern of change in Hb concentration during the first year of ADT of M1b prostate cancer may be an independent predictor of survival.
Patients and Methods
This study was based on the Scandinavian Prostate Cancer Group (SPCG) Trial number 5, a Phase III study in which 915 men with hormone-naive M1b prostate cancer were included from 61 centres in Denmark, Finland, Iceland, Norway and Sweden between December 1992 and June 1997 [18] [19] [20] . The SPCG-5 was designed as a noninferiority trial. Inclusion criteria were skeletal metastases (M1b) and an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0-2, where: 0 = fully active; 1 = restriction in strenuous activity but ambulatory; and 2 = ambulatory and capable of self-care but unable to work. The primary objective of the trial was to determine whether survival after high-dose parenteral oestrogen therapy was not inferior to that after total androgen blockade (TAB) [18] [19] [20] . The secondary objective was to provide information on cardiovascular side-effects and health-related quality of life (QoL) before and during ADT [19] .
The extent of the primary tumour was determined using DRE according to the TNM classification from 1987 and cytological or histological specimens graded according to the WHO system. PSA, alkaline phosphatase (ALP), testosterone and Hb levels were determined by routine laboratory testing before the start of treatment [18, 19] . Skeletal involvement was assessed using bone scans supplemented by X-ray in selected cases [18] [19] [20] . The extent of bone metastases was quantified according to a modified three-grade Soloway Score where: 1 = the total area of hot spots <3 lumbar vertebral bodies; 2 = the total area of hot spots larger than Score 1, but <75% of the total scan; and 3 = ≥75% of the total scan or super scan. QoL was rated by The European Organisation of Research and Treatment of Cancer Quality-of-Life Questionnaire 30-item core (C30) [18, 19] .
The patients were randomised to TAB or treatment with polyoestradiol phosphate (PEP; 240 mg) given as an intramuscular injection every 2 weeks for 8 weeks, and monthly thereafter. TAB was as achieved by bilateral orchidectomy or medical castration with the LHRH agonist triptorelin, according to clinician and patient preference, combined with 250 mg flutamide orally three-times daily. In the TAB group, 298 patients chose orchidectomy, and 159 men chose medical castration.
The men were followed up at 1, 3 and 6 months after the start of the study, and thereafter every 6 months. Hb and testosterone levels were taken during the first year of followup at some of the centres. When clinical progression of prostate cancer was confirmed, further therapy was at the discretion of the clinician. All 915 patients were to be followed until death.
From the 915 trial patients, we identified 597 men who had Hb concentrations at enrolment and at 3, 6 and 12 months of ADT in the database.
Ethics
This study was performed in accordance with the recommendations of the Helsinki Declaration and approved by the ethics committees of all centres participating in the study. Patients were given verbal and written information, and gave their informed consent to be included in the study [18] [19] [20] .
Statistical Methods
The study cohort comprised 597 men where Hb concentrations at start of treatment and at 3, 6 and 12 months existed in the trial's database.
Boxplots were used to visualise Hb concentrations and changes over time. Associations between changes in Hb concentration over the three periods 0-3, 3-6 and 584 © 2018 The Authors BJU International © 2018 BJU International 6-12 months and predetermined baseline clinical parameters were evaluated by using multivariate linear regression models. The clinical parameters analysed were age at enrolment, treatment, cancer-related pain, ECOG PS, analgesic consumption, grade of malignancy, T category, Modified Soloway Score, and PSA, ALP, Hb, and testosterone levels. The primary outcome was overall survival (OS), which was defined as the interval between the date of enrolment and the date of death or end of the 10-year follow-up, whichever came first. Associations between changes in Hb concentration at 3, 6 and 12 months of ADT and survival were evaluated using Kaplan-Meier curves and multivariate Cox regression models. In a separate Cox regression model, Hb concentration was considered a time-dependent variable, adjusting for all the baseline clinical parameters. All P values were two-sided and statistical significance was considered at P < 0.05. All analyses were performed using the R version 3.1.1. (R Foundation for Statistical Computing, Vienna, Austria).
Results

Clinical Characteristics
Baseline demographic and clinical characteristics of the 597 patients included in the study are presented in Table 1 . The mean age at enrolment was 71.9 years, and most of the patients had cancer-related pain, a modified Soloway Score >1, a WHO System Grade of 2-3, and had a locally advanced tumour (T3-T4).
Advanced age at diagnosis, cancer-related pain, analgesic consumption, ECOG PS 1-3, cardiovascular morbidity, high Modified Soloway Score, high PSA and ALP levels, were all associated with low Hb concentrations at baseline (all P < 0.05). Testosterone and treatment were, however, not associated with the Hb concentration.
The mean Hb concentration was higher at baseline than at 3, 6 and 12 months (Fig. 1A) , and there was little difference in mean change in Hb concentration over the three study periods 0-3, 3-6 and 6-12 months, respectively (Fig. 1B) .
Predicting Change in Hb Concentrations
Three separate multivariate linear regression models for the predetermined clinical parameters were fitted with the change in Hb concentration over the three study periods (Table 2 ). Higher baseline Hb concentration, TAB treatment, increasing age, and higher testosterone level were associated with a fall in Hb concentration over the first 3-month period, TAB treatment, analgesic consumption, and PSA level were associated with fall in Hb concentration over the period 3-6 months, but, apart from analgesic consumption, there were no associations between the clinical parameters and the change in Hb concentration between 6 and 12 months.
Changes in Hb Concentration as a Predictor of Survival
The impact of change in Hb concentration over time on OS is shown as Kaplan-Meier curves in Figure 2 . Figure 2A shows a significantly poorer survival in patients with an increase in Hb concentration during the first 3-month period and on the contrary better survival in patients with an increase in Hb during the last 6-month period ( Figure 2C ). Increase in Hb concentration between 3 and 6 months had no significant impact on survival ( Figure 2B ). Multivariate Cox proportional hazard analyses of OS according to change in Hb concentration over the three study periods as a timedependent variable are presented in Table 3 . After adjustment for potential clinical confounders, we observed better survival amongst patients with a decrease in Hb concentration during the first period (HR 1.42, CI 95% 1.11-1.80), no association between Hb concentration and mortality was observed for the period 3-6 months (HR 0.93, 95% CI 0.76-1.12), whereas a poorer survival for patients with a decrease in Hb concentration between 6 and 12 months was seen (HR 0.76, 95% CI 0.62-0.92).
Discussion
The present study confirms the impact of changes in Hb concentration on the prognosis of men receiving ADT for M1b prostate cancer. When deciding on treatment of men with M1b prostate cancer, the effect of antiandrogen therapy Higher baseline Hb concentration, TAB treatment, increasing age, and higher testosterone level were associated with a fall in Hb concentration during the first 3 months of ADT (Table 2) . TAB treatment, analgesic consumption, and PSA levels were associated with a decrease in Hb concentration between 3 and 6 months. Apart from need for analgesia no baseline parameter was associated with changes in Hb concentration over the last 6 months.
Anaemia may be secondary not only to the prostate cancer per se, but also the antiandrogen therapy [10] . The fall in Hb concentration after initiation of ADT thus reflects response to treatment, whilst also being one of the reasons for decreased performance status during progression of the disease.
After adjustment for potential clinical confounders, we observed a higher overall mortality risk amongst patients with an increase in Hb concentration between 0 and 3 months (HR 1.42, 95% CI 1.11-1.80), whilst no difference in risk was observed between 3 and 6 months (HR 0.93, 95% CI 0.76-1.12). However, an increase in Hb over the last 6 months was associated with a lower mortality risk (HR 0.76, 95% CI 0.62-0.92).
Beer et al. [17] did post hoc analyses of data from the SWOG 8894 trial (comparing medical or surgical castration with or without the antiandrogen flutamide) to assess whether specific baseline characteristics or changes in Hb during ADT affected survival. These analyses showed shorter survival in patients with anaemia prior to starting ADT. In addition to baseline Hb concentration [17, 21] , a fall in Hb concentration after 3 months of ADT was independently associated with shorter survival [17] . An unexpected complex association between Hb concentrations during the first 3 months of ADT and survival was identified. As a rule anaemia is not in the list of the most common side-effects of different forms of ADT in clinical trials. However, in one study 22 the percentage of patients with anaemia was significantly higher in the group receiving flutamide and orchidectomy compared to the group who received orchidectomy and placebo. However, as yet, the clinical significance and association with survival of changes in Hb concentration over a period of ADT >3 months has not been investigated.
In contrast to the conclusions of many other studies [17, 21] , we found that a fall in Hb over the first 3 months of ADT was related to better OS, whereas a fall in Hb over the period 6-12 months was associated with poorer OS. Anaemia is a known side-effect of ADT [6] . It may be assumed that a good response to treatment, i.e. a significant decline in testosterone level, is also associated with tumour response as well as sideeffects due to ADT such as the effect on the haematopoietic system with anaemia. Any fall in Hb concentration after 6 months of ADT is more likely to be due to the disease itself rather than a side-effect of the treatment. We were unable to test this possibility, as testosterone levels were not measured routinely in the SPCG-5 trial.
Other studies have compared the effects of radiation alone to radiation plus TAB on Hb concentration, erythropoietin (EPO) and testosterone levels in patients with localised prostate cancer [23] . They saw a decline in testosterone after 4 5 6 7 8 9 10 No. at risk © 2018 The Authors BJU International © 2018 BJU International 587 1 month of TAB followed by a significant fall in Hb concentration after 3-6 months, even though there was a small but statistically significant increase in serum EPO. No changes in either Hb concentration or testosterone levels were seen in the radiation-alone group.
Anaemia is a known adverse effect of ADT, consistent with the androgen dependency of the haemopoietic system [6] . The Hb concentration at diagnosis is one of the conventional pre-treatment risk factors [21] . However, in a number of recent large randomised trials on different forms of ADT of hormone-na€ ıve M1b prostate cancer, the patients were not stratified for Hb concentration [18] .
The relationship between Hb concentration before and 3 months after the start of treatment and survival was explored in analyses of outcomes of patients enrolled in the randomised clinical trial SWOG 8894 comparing two types of ADT. Contrary to the outcome of the present study, the SWOG 8894 study showed poorer survival in patients with anaemia before commencing ADT [17, 21] , and furthermore a fall in Hb concentration after 3 months of ADT was independently associated with shorter survival [17] . However, the clinical significance of Hb concentration changes over >3 months of ADT has to date not been investigated.
Bone metastasis is a common manifestation in patients with advanced prostate cancer, influencing bone marrow function and contributing to changes in Hb concentration (either an increase or decrease). Some retrospective and prospective studies have focused on pretreatment Hb concentration as a prognostic factor for patients with prostate cancer undergoing ADT in univariate or multivariate analyses, and a low pretreatment Hb concentration has been found to a predictor of poor outcome. However, a number of large randomised clinical trials on ADT in hormone-na€ ıve M1b prostate cancer have found the extent of bone metastases to be the dominant predictor of mortality. These study patients were not grouped according to Hb concentration at randomisation, but it was later shown in two separate analyses of the SWOG 8894 trial that anaemia before commencing treatment was associated with shorter survival. Contrary to our present results, that study also showed that a fall in Hb concentration after 3 months of ADT treatment was also associated with poorer outcome.
Until now the clinical importance of changes in Hb concentration beyond 3 months of treatment and their association with survival has not been described.
Limitations
Our present results do not provide a pathophysiological explanation for the changes in Hb concentration seen with time. We propose that these changes are dominated by the influence of ADT on tumour activity. The exact degree of the direct influence of androgen withdrawal on Hb concentrations could not be determined. Furthermore, we did not have data on detailed numbers and locations of bone metastases and could therefore not say whether they were axial (pelvic bones and spine) or appendicular (long bones, skull), which has been shown to be a discriminating factor between risk groups in other trials. Visceral and non-regional lymph node metastases were not evaluated at inclusion in the present study. However, to date, the significance of metastatic site on survival has not been comprehensibly addressed in prospective studies.
Our present study was not designed to determine the underlying cause for the observed Hb concentration changes. However, the lack of testosterone after ADT is associated with significant but mild decrease of Hb concentration. Awareness of this effect may prevent unnecessary diagnostic evaluations. In symptomatic men with severe anaemia treatment may be warranted. Deficiencies such as iron and vitamin B 12 /folate should be substituted by oral or parenteral supplementation. For patients who have not been considered transfusion dependent, the use of EPO may be beneficial. Regular blood transfusions may be the only effective measure in patients with limited bone marrow reserve. Whether treating anaemia by different means could improve prostate cancer-specific survival remains unknown. Convincing randomised prospective studies on these topics are lacking.
Strength of the Study
Our present prognostic model was based on a large dataset from a relatively homogeneous patient population with follow-up over a long period with a sufficient event rate. Where most studies have looked at changes in Hb concentration over the first 3 months of ADT only, our present study provides information about changes in Hb concentration up to a year after commencement of ADT.
The present study does not conclude whether or not treatment of anaemia improves prognosis, when treatment should be introduced, and how best to treat the condition (EPO/blood transfusion/iron substitution). Other studies have also shown a fall in Hb concentration following ADT treatment [4, 15] . In these studies, 37% [4] and 13% [15] of patients had symptoms arising from anaemia. In the study by Curtis et al. [5] , anaemia and its symptoms were easily managed by the subcutaneous administration of EPO, and the authors recommend that practitioners monitor Hb concentration during ADT and treat symptomatic patients.
Another study [6] looked into haematological changes during ADT and their adverse effects. They also noticed a significant drop in Hb concentration during ADT treatment. However, there was no significant correlation between anaemia and QoL or fatigue in these patients.
Conclusion
In a large cohort of Scandinavian men with hormone-na€ ıve M1b prostate cancer, Hb concentration at diagnosis was significantly related to OS. Increase in Hb concentration between baseline and 3 months of ADT was associated with poorer survival, whereas an increase between 6 and 12 months gave a better prognosis. These findings provide new information about associations between changes in Hb concentrations and survival over 12 months of ADT for M1b prostate cancer. Clinicians should be aware of the significance of changes in Hb concentration over the first year of ADT, and its use as a predictor of survival.
